Brain Tissue

The transformative capability of cOFM lies in its unique ability to sample cerebral interstitial fluid while maintaining an intact BBB—a critical distinction that addresses one of neuropharmaceutical development’s most persistent challenges. While the BBB serves as the brain’s essential protective shield, it simultaneously creates a formidable obstacle for drug delivery. Traditional sampling methods that rupture the BBB during measurement fundamentally alter the very system they seek to evaluate. cOFM solves this paradox through a carefully designed protocol: after initial probe implantation into the target brain region, a two-week healing period allows the BBB to fully re-establish itself before sampling begins, ensuring that all subsequent measurements reflect true drug transport dynamics across an intact BBB.

The membrane-free design of cOFM probes represents another crucial advancement over conventional microdialysis techniques. During sampling, the probe is continuously perfused with physiological fluid that exchanges molecules directly with the cerebral interstitial fluid along the exchange area of the probe. The collected samples thus contain the complete molecular spectrum present in brain tissue including drugs, proteins, antibodies, nanocarriers, and metabolites without any restrictions imposed by molecular size, lipophilicity, or protein-binding properties. This unfiltered access to the entire biochemical information of the brain’s interstitial environment delivers the comprehensive data essential for understanding complex drug-tissue interactions.

cOFM’s capacity for longitudinal sampling extends up to several weeks, generating time-resolved, high-quality concentration profiles that capture both pharmacokinetic and pharmacodynamic effects over clinically relevant timeframes. This temporal resolution is particularly valuable for assessing novel delivery systems, such as nanoformulations that have been successfully measured crossing the BBB using cOFM technology. The ability to sample from multiple specific brain regions while maintaining BBB integrity provides researchers with unprecedented temporal data, enabling precise characterization of regional drug distribution, local metabolism, and therapeutic response in both healthy brain tissue and pathological conditions including tumors. This combination of intact BBB assessment, unrestricted molecular sampling, and extended monitoring capability establishes cOFM as an indispensable tool for advancing CNS drug discovery from preclinical development to clinical translation.